Marcin Zychma

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

John B. Buse, Julio Rosenstock, Giorgio Sesti et al. · The Lancet · 2009 · 1.5K citations

Open-label Trial, Diabetes Management, Medicine +6

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

J. Hans DeVries, Stephen C. Bain, Helena W. Rodbard et al. · Diabetes Care · 2012 · 158 citations · Full text

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16‐week, randomized, double‐blind, active control trial ^*

Wenying Yang, L. Chen, Qiuhe Ji et al. · Diabetes Obesity and Metabolism · 2010 · 90 citations

Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: Risk of chronic renal failure

Janusz Gumprecht, Marcin Zychma, W Grzeszczak et al. · Kidney International · 2000 · 52 citations · Full text

Angiotensinogen M235t Polymorphisms, Hypertension, Urology +14

The role of aldose reductase gene in the susceptibility to diabetic nephropathy in Type II (non-insulin-dependent) diabetes mellitus (Short Communication)

Dariusz Moczulski, W Burak, Alessandro Doria et al. · Diabetologia · 1999 · 50 citations · Full text

Metabolic Syndrome, Aldose Reductase Gene, Renal Disease +13